Last reviewed · How we verify
Zonegran
Zonegran is a Small molecule drug developed by Dr. Reddy's Laboratories Limited. It is currently FDA-approved for Diffuse Lewy body disease, Partial Epilepsy Treatment Adjunct. Also known as: zonisamide.
At a glance
| Generic name | Zonegran |
|---|---|
| Also known as | zonisamide |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Target | Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Diffuse Lewy body disease
- Partial Epilepsy Treatment Adjunct
Common side effects
- Somnolence
- Anorexia
- Dizziness
- Ataxia
- Agitation/Irritability
- Difficulty with memory and/or concentration
- Fatigue
- Nausea/Vomiting
- Weight loss
- Mental slowing
- Accidental injury
- Asthenia
Serious adverse events
- Lupus erythematosus
- Pulmonary embolus
- Heart failure
- Atrial fibrillation
- Thrombocytopenia
- Cholestatic jaundice
- Hematemesis
- Hyponatremia
- Syncope
- Thrombophlebitis
Key clinical trials
- Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures (PHASE4)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) (PHASE2)
- The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (PHASE3)
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures (PHASE4)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (PHASE2)
- The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zonegran CI brief — competitive landscape report
- Zonegran updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI
Frequently asked questions about Zonegran
What is Zonegran?
Zonegran is a Small molecule drug developed by Dr. Reddy's Laboratories Limited, indicated for Diffuse Lewy body disease, Partial Epilepsy Treatment Adjunct.
What is Zonegran used for?
Zonegran is indicated for Diffuse Lewy body disease, Partial Epilepsy Treatment Adjunct.
Who makes Zonegran?
Zonegran is developed and marketed by Dr. Reddy's Laboratories Limited (see full Dr. Reddy's Laboratories Limited pipeline at /company/dr-reddy-s-laboratories-limited).
Is Zonegran also known as anything else?
Zonegran is also known as zonisamide.
What development phase is Zonegran in?
Zonegran is FDA-approved (marketed).
What are the side effects of Zonegran?
Common side effects of Zonegran include Somnolence, Anorexia, Dizziness, Ataxia, Agitation/Irritability, Difficulty with memory and/or concentration. Serious adverse events: Lupus erythematosus, Pulmonary embolus, Heart failure, Atrial fibrillation.
What does Zonegran target?
Zonegran targets Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12.
Related
- Target: All drugs targeting Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12
- Manufacturer: Dr. Reddy's Laboratories Limited — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Diffuse Lewy body disease
- Indication: Drugs for Partial Epilepsy Treatment Adjunct
- Also known as: zonisamide